Value Investing News

Lung Cancer is the number one cancer killer globally, claiming approximately 1.2 million lives annually. Non-Small Cell Lung Cancer (NSCLC) is the most common, accounting for 85% of lung cancers. Abraxis Bioscience was a biopharmaceutical company that was recently purchased by Celgene Corp. (CELG).

• http://www.frankvoisin.com/2010/12/21/celgene-corp-celg-contingent-value-rights/ (308)